Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
The latest news, research, and perspectives in chronic lymphocytic leukemia (CLL). The most common leukemia subtype among adults, CLL occurs when an acquired mutation causes bone marrow to produce abnormal lymphocytes. As these leukemic cells proliferate, the disorder is associated with lymphadenopathy, splenomegaly, and cytopenias.
Advertisement
Melissa BadamoChronic Lymphocytic Leukemia | January 3, 2025
The research projects aim to improve patient quality of life, address treatment disparities, and increase access to care.
Melissa BadamoChronic Lymphocytic Leukemia | December 18, 2024
First-line, fixed-duration ibrutinib plus venetoclax provides durable PFS and OS for patients with CLL.
Melissa BadamoChronic Lymphocytic Leukemia | December 18, 2024
Venetoclax plus obinutuzumab demonstrates superior safety and efficacy compared with FCR and BR in untreated CLL.
Melissa BadamoChronic Lymphocytic Leukemia | December 18, 2024
Fewer patients in the acalabrutinib group experienced treatment-emergent cardiovascular medical events after BTKi initiation.
Nichole TuckerChronic Lymphocytic Leukemia | December 17, 2024
Results observed in the phase 3 AMPLIFY provide evidence for the all-oral approach to CLL treatment.
Nichole TuckerChronic Lymphocytic Leukemia | December 17, 2024
Real-world data and clinical trial data may support less TLS monitoring in patients with CLL who receive venetoclax.
Advertisement
Nichole TuckerChronic Lymphocytic Leukemia | December 17, 2024
In addition to continued efficacy, zanubrutinib was well tolerated by patients with treatment-naive CLL and SLL.
Nichole TuckerChronic Lymphocytic Leukemia | December 12, 2024
CTX112, a next-generation allogeneic CRISPR-Cas9–engineered showing encouraging results in B-cell malignancies.
Nichole TuckerChronic Lymphocytic Leukemia | December 8, 2024
Results from the TRANSCEND CLL 004 show continued benefit of lisocabtagene maraleucel for R/R CLL treatment.
Julie GouldMeeting News | December 6, 2024
A study stresses psychological support as an essential component of comprehensive cancer care.
Melissa BadamoChronic Lymphocytic Leukemia | December 3, 2024
Pirtobrutinib demonstrated a significant improvement in PFS and a more favorable safety profile than IC regimens.
Patrick DalyChronic Lymphocytic Leukemia | November 27, 2024
Anti-CD19 CAR T-cell therapy appeared to cure a significant number of patients with relapsed or refractory CLL.
Andrew MorenoChronic Lymphocytic Leukemia | November 27, 2024
Pinpointing the driver of pro-survival protein upregulation in CLL cells may lead to more effective combination therapies.
Andrew MorenoChronic Lymphocytic Leukemia | December 13, 2024
In the EPCORE CLL‑1 trial's expansion and optimization cohorts, no patients discontinued therapy due to CRS, ICANS, or ...
Leah LawrencePrint | November 18, 2024
The interest in using quantitative tests to measure residual cancer cells continues to expand in the arena of blood cancers.
Andrew MorenoChronic Lymphocytic Leukemia | November 13, 2024
Venetoclax plus ibrutinib was associated with lower rates of mortality and serious adverse events than the control regimens.
Melissa BadamoChronic Lymphocytic Leukemia | October 23, 2024
The combination of atezolizumab, venetoclax, and obinutuzumab was found to be safe and active in Richter transformation.
Melissa BadamoChronic Lymphocytic Leukemia | October 23, 2024
The ORR was 85.6% for the zanubrutinib group, compared to 75.4% for the ibrutinib group.
Melissa BadamoChronic Lymphocytic Leukemia | October 22, 2024
Pirtobrutinib achieved high response rates in patients with CLL or SLL who are intolerant to prior BTKis.
Adam Kittai, MDChronic Lymphocytic Leukemia | October 8, 2024
Adam Kittai, MD, discusses sequencing pirtobrutinib and CAR-T in the management of CLL with Richter transformation.
Advertisement
Advertisement
Editorial Board